Table 4. The 3-, 5-, 10-year DS rates in histological subtypes.
| Histological subtypes | 3-year DS, % | 5-year DS, % | 10-year DS, % |
|---|---|---|---|
| EOC | |||
| Serous | 65.0 | 49.1 | 33.9 |
| Endometrioid | 90.6 | 86.0 | 80.1 |
| Mucinous | 78.8 | 75.4 | 70.5 |
| Clear cell | 76.1 | 69.3 | 65.0 |
| Malignant Brenner | 89.8 | 81.3 | 75.4 |
| Undifferentiated carcinoma | 59.0 | 49.2 | 37.7 |
| Mixed | 92.0 | 66.7 | 57.0 |
| Carcinosarcoma | 43.0 | 32.3 | 25.1 |
| MOGCT | |||
| Dysgerminoma | 98.4 | 98.4 | 98.4 |
| Embryonal carcinoma | 66.7 | 66.7 | 66.7 |
| Yolk sac tumor | 90.7 | 86.7 | 85.6 |
| Malignant teratoma | 96.0 | 95.5 | 95.1 |
| Mixed germ cell tumor | 96.0 | 95.2 | 95.2 |
| MOSCST | |||
| Granulosa cell tumor | 92.4 | 90.3 | 85.9 |
| PDSLCT | 81.7 | 80.2 | 75.7 |
| ONT | |||
| Carcinoid tumor | 97.2 | 95.8 | 95.8 |
| LCNEC | 21.8 | 21.8 | 21.8 |
| SCNEC | 28.0 | 26.4 | 21.1 |
DS, disease-specific survival; EOC, epithelial ovarian carcinoma; MOGCT, malignant ovarian germ cell tumor; MOSCST, malignant ovarian sex cord-stromal tumor; PDSLCT, poorly-differentiated Sertoli-Leydig cell tumor; ONT, ovarian neuroendocrine tumor; LCNEC, large cell neuroendocrine carcinoma; SCNEC, small cell neuroendocrine carcinoma.